Functional and isokinetic assessment of muscle strength in patients with idiopathic inflammatory myopathies

Autoimmunity

Volumn 39, Issue 3, 2006, Pages 255-259

  Neri, R ^a   Mosca, Marta ^a   Stampacchia, G ^a   Vesprini, E ^a   Tavoni, A ^a   D'Ascanio, A ^a   Bombardieri, S ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Functional outcome; Health assessment questionnaire; Idiopathic inflammatory myopathies; Isokinetic assessment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; IDIOPATHIC DISEASE; ISOKINETIC EXERCISE; MALE; MUSCLE FUNCTION; MUSCLE LENGTH; MYOSITIS; QUESTIONNAIRE; RATING SCALE; SENSITIVITY ANALYSIS;

ADRENAL CORTEX HORMONES; ADULT; AGED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYOSITIS;

EID: 33745114688     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930600623817     Document Type: Article

References (32)

1. Plotz, PH and Rider, LG and Targoff, IN and Raben, N and O'Hanlon, TP and Miller, FW and Conference, NIH. (1995) Myositis: Immunologic contributions to understanding its cause, pathogenesis, and therapy Ann Intern Med, 122(9), pp. 715-724.
2. Miller, FW. (1994) Classification and prognosis of inflammatory muscle disease Rheum Dis Clin North Am, 20(4), pp. 811-823.
3. Targoff, IN and Miller, FW and Medsger, TA and Oddis, CV. (1997) Classification criteria for the idiopathic inflammatory myopathies Curr Opin Rheumatol, 9, pp. 527-535.
4. Dalakas, MC and Hohlfeld, R. (2003) Polymyositis and dermatomyositis Lancet, 362, pp. 971-982.
5. Studynková, JT and Kuchen, S and Jeisy, E and Schedel, J and Charvát, F and Jarosová, K and et al. (2004) The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis Clin Exp Rheumatol, 22, pp. 395-402.
6. Zampieri, S and Ghirardello, A and Iaccarino, L and Tarricone, E and Gambari, PF and Doria, A. (2005) Anti-JO-1 antibodies Autoimmunity, 38, pp. 73-78.
7. Vered, M and Yehuda, S. (2005) Infection, vaccines and other environmental triggers of autoimmunity Autoimmunity, 38, pp. 235-245.
8. Ponyi, A and Borgulya, G and Constantin, T and Vancsa, A and Gergely, L and Danko, K. (2005) Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis Rheumatology, 44, pp. 83-88.
9. Ramanan, AV and Feldman, BM. (2002) Clinical outcomes in juvenile dermatomyositis Curr Opin Rheumatol, 14, pp. 658-662.
10. Ruperto, N and Ravelli, A and Murray, KJ and Lovell, DJ and Andersson-Gare, B and Feldmnn, BM and et al. (2003) Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis Rheumatology, 42, pp. 1452-1459.
11. Ponyi, A and Constantin, T and Balogh, Z and Szalai, Z and Borgulya, G and Molnar, K and et al. (2005) Disease course, frequency of relapses and survival of 73 patients with juvenile or adult dermatomyositis Clin Exp Rheumatol, 23, pp. 50-56.
12. Moxley, RT. (1994) Evaluation of neuromuscular function in inflammatory myopathy Rheum Dis Clin North Am, 20(4), pp. 827-843.
13. Drouet, B and Le Loet, X and Vittecoq, O and Nuovet, G and Lauret, P and Tron, P and et al. (1996) A study of long-term survival, functional outcome and quality of life in patients with polymyositis and dermatomyositis Rev Rhum Engl Ed, 63, pp. 321-330.
14. Fafalak, RG and Peterson, MGE and Kagen, LJ. (1994) Strength in polymyositis and dermatomyositis: Best outcome in patients treated early J Rheumatol, 21, pp. 643-648.
15. Badrising, UA and Maat-Schieman, MLC and Ferrari, MD and Zwinderman, AH and Wessels, JAM and Breedveld, FC and et al. (2002) Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo Ann Neurol, 51, pp. 369-372.
16. Nzeusseu, A and Brion, F and Lefebvre, C and Knoops, P and Devogelaer, JP and Houssiau, FA. (1999) Functional outcome of myositis patients: Can a low-dose glucocorticoid regimen achieve good functional results? Clin Exp Rheumatol, 17, pp. 441-446.
17. Maugars, YM and Berthelot, JM and Abbas, AA and Mussini, JM and Nguyen, JM and Prost, AM. (1996) Long-term prognosis of 69 patients with dermatomyositis or polymyositis Clin Exp Rheumatol, 14, pp. 263-274.
18. Rider, LG and Giannini, EH and Brunner, EI and Ruperto, N and James-Newton, L and Reed, AM and et al. (2004) International consensus on preliminary definitions of improvement in adult and juvenile myositis Arthritis Rheum, 50, pp. 2281-2290.
19. Huber, AM and Feldman, BM and Rennebohm, RM and Hicks, JE and Lindsley, CB and Perez, MD and et al. (2004) Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies Arthritis Rheum, 50, pp. 1595-1603.
20. Gaines, JM and Talbot, LA. (1999) Isokinetic strength testing in research and practice Biol Res Nurs, 1, pp. 57-64.
21. Wiesenger, GF and Quittan, M and Aringer, M and Seeber, A and Volc-Platzer, B and Smolen, J and et al. (1998) Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme Br J Rheumatol, 37, pp. 196-200.
22. Wiesenger, GF and Quittan, M and Nhur, M and Volc-Platzer, B and Ebenbichler, G and Zehetgruber, M and et al. (2000) Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls Arch Phys Med Rehabil, 81, pp. 1-5.
23. Bohan, A and Peter, JB. (1975) Polymyositis and dermatomyositis N Engl J Med, 292, pp. 344-347.
24. Bohan, A and Peter, JB. (1975) Polymyositis and dermatomyositis N Engl J Med, 292, pp. 403-407.
25. Neri, R and Mosca, M and Grazzini, T and Tavoni, A and Pasero, G and Bombardieri, S. (2001) Outcome funzionale a lungo termine delle miopatie infiammatorie idiopatiche. Long term functional outcome of idiopathic inflammatory myopathies Reumatismo, 53, pp. 40-45.
26. Henriksson, KG and Sandstedt, P. (1982) Polymyositis treatment and prognosis. A study of 107 patients Acta Neurol Scand, 65, pp. 280-300.
27. Kannus, P. (1994) Isokinetic evaluation of muscular performance: Implications for muscle testing and rehabilitation Int J Sports Med, 15 S 1, pp. S11-S18.
28. Stoll, T and Bruhlmann, P and Stucki, G and Seifert, B and Michel, BA. (1995) Muscle strength assessment in polymyositis and dermatomyositis: Evaluation of the reliability and clinical use of a new, quantitative, easily applicable method J Rheumatol, 22, pp. 473-477.
29. Jepsen, J and Laursen, L and Larsen, A and Hagert, CG. (2004) Manual strength testing in 14 upper limb muscles: A study of inter-rater reliability Acta Orthop Scand, 75, pp. 442-448.
30. Sultan, SM. (2003) The assessment and importance of disease activity versus disease damage in patients with inflammatory myopathy Curr Rheumatol Rep, 5, pp. 445-450.
31. Kannus, P. (1992) Normality, variability and predictability of work, power and torque acceleration energy with respect to peak torque in isokinetic muscle testing Int J Sports Med, 13, pp. 249-256.
32. Oddis, CV. (1994) Therapy of inflammatory myopathy Rheum Dis Clin North Am, 20(4), pp. 899-917.